Breakthrough dementia drugs ‘will be useless for 80 per cent’ warn top British experts

Donanemab and lecanemab have both been proven to slow the progress of the memory-robbing illness in its early stages. They are expected to be approved this year. Donanemab and lecanemab have both been proven to slow the progress of the memory-robbing illness in its early stages. They are expected to be approved this year.